We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Market for IHC Tests Growing in Europe

By Labmedica staff writers
Posted on 31 Mar 2006
Print article
Immunohistochemistry (IHC) is emerging as an important tool for cancer diagnostics in Europe, following the development of new-generation diagnostic kits that can detect cancer at its earliest stages, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), an international consulting firm.

Recent campaigns in Europe that improved patient management by encouraging people to test themselves for certain subtypes of cancer indicate that the focus of IHC diagnostics should be on early detection and treatment. Market revenues for IHC diagnostics are forecast to increase to U.S.$48.1 million by 2011 at an estimated compound annual growth rate of 4.7%.

"Timely disease detection offers compelling advantages such as reduced need for expensive therapies” said Frost & Sullivan research analyst Dr. Fiona Rahman. "This in turn brings down bed occupancy rates and reduces the burden on the healthcare system, driving governments to implement national cancer-screening programs across Europe.”

The IHC diagnostics market in Europe is highly competitive and manufacturers need to train company personnel who can educate end users on their products. Conferences or focus groups are being organized that provide a platform for clinicians, laboratory technicians, administrators, and product specialists to interact with each other and to become familiar with the latest practices and techniques in IHC testing.

The cost of IHC tests is higher than that of traditional testing methods. Dr. Rahman observes that companies will need to improve the automation of these tests radically to be competitive with more conventional technologies. "While physicians are reluctant to experiment with expensive IHC products, they are nevertheless essential to complement more traditional diagnostic methods” said Dr. Rahman. "The challenge for manufacturers, therefore, is to offer IHC products at cost-effective prices to encourage end users to experiment and successfully adopt these tests as routine diagnosis”


Related Links:
Frost and Sullivan
Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.